cis-Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects

We have identified unique chemical and biological properties of a cationic monofunctional platinum(II) complex, cis-diammine(pyridine)chloroplatinum(II), cis-[Pt(NH3)2(py)Cl]+ or cDPCP, a coordination compound previously identified to have significant anticancer activity in a mouse tumor model. This compound is an excellent substrate for organic cation transporters 1 and 2, also designated SLC22A1 and SLC22A2, respectively. These transporters are abundantly expressed in human colorectal cancers, where they mediate uptake of oxaliplatin, cis-[Pt(DACH)(oxalate)] (DACH = trans-R,R-1,2-diaminocyclohexane), an FDA-approved first-line therapy for colorectal cancer. Unlike oxaliplatin, however, cDPCP binds DNA monofunctionally, as revealed by an x-ray crystal structure of cis-{Pt(NH3)2(py)}2+ bound to the N7 atom of a single guanosine residue in a DNA dodecamer duplex. Although the quaternary structure resembles that of B-form DNA, there is a base-pair step to the 5′ side of the Pt adduct with abnormally large shift and slide values, features characteristic of cisplatin intrastrand cross-links. cDPCP effectively blocks transcription from DNA templates carrying adducts of the complex, unlike DNA lesions of other monofunctional platinum(II) compounds like {Pt(dien)}2+. cDPCP–DNA adducts are removed by the nucleotide excision repair apparatus, albeit much less efficiently than bifunctional platinum–DNA intrastrand cross-links. These exceptional characteristics indicate that cDPCP and related complexes merit consideration as therapeutic options for treating colorectal and other cancers bearing appropriate cation transporters.

[1]  P. Cramer,et al.  Mechanism of transcriptional stalling at cisplatin-damaged DNA , 2007, Nature Structural &Molecular Biology.

[2]  L. Kèlland,et al.  The resurgence of platinum-based cancer chemotherapy , 2007, Nature Reviews Cancer.

[3]  D. Gandara,et al.  Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  T. Pawlik,et al.  Chemotherapy‐associated hepatotoxicity and surgery for colorectal liver metastases , 2007, The British journal of surgery.

[5]  Craig D. Kaplan,et al.  Structural Basis of Transcription: Role of the Trigger Loop in Substrate Specificity and Catalysis , 2006, Cell.

[6]  N. Margiotta,et al.  Sterically hindered complexes of platinum(II) with planar heterocyclic nitrogen donors. A novel complex with 1-methyl-cytosine has a spectrum of activity different from cisplatin and is able of overcoming acquired cisplatin resistance. , 2006, Journal of inorganic biochemistry.

[7]  Shuzhong Zhang,et al.  Organic cation transporters are determinants of oxaliplatin cytotoxicity. , 2006, Cancer research.

[8]  R. Rosell,et al.  Predicting the outcome of chemotherapy for lung cancer. , 2006, Current opinion in pharmacology.

[9]  R. Neubert,et al.  Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). , 2005, Biochemical pharmacology.

[10]  Dong Wang,et al.  Cellular processing of platinum anticancer drugs , 2005, Nature Reviews Drug Discovery.

[11]  D. Lane,et al.  Transcription — guarding the genome by sensing DNA damage , 2004, Nature Reviews Cancer.

[12]  Thomas Ludwig,et al.  Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. , 2004, Kidney international.

[13]  Dong Wang,et al.  Nucleotide excision repair from site-specifically platinum-modified nucleosomes. , 2003, Biochemistry.

[14]  Conrad C. Huang,et al.  Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Adam P. Silverman,et al.  2.4-Å Crystal Structure of the Asymmetric Platinum Complex {Pt(ammine)(cyclohexylamine)}2+ Bound to a Dodecamer DNA Duplex* , 2002, The Journal of Biological Chemistry.

[16]  P. Sharp,et al.  Transcription-coupled and DNA damage-dependent ubiquitination of RNA polymerase II in vitro , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[17]  S. Lippard,et al.  2.4 A crystal structure of an oxaliplatin 1,2-d(GpG) intrastrand cross-link in a DNA dodecamer duplex. , 2001, Inorganic chemistry.

[18]  J. Essigmann,et al.  Mechanisms of resistance to cisplatin. , 2001, Mutation research.

[19]  K. Giacomini,et al.  Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. , 2001, Journal of pharmaceutical sciences.

[20]  L. Marzilli,et al.  Relationship of solution and protein-bound structures of DNA duplexes with the major intrastrand cross-link lesions formed on cisplatin binding to DNA. , 2001, Journal of the American Chemical Society.

[21]  J. Perez,et al.  Current status of the development of trans-platinum antitumor drugs. , 2000, Critical reviews in oncology/hematology.

[22]  S. Chaney,et al.  Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. , 1999, Cancer research.

[23]  A. Wang,et al.  Monofunctional platinum amine complexes destabilize DNA significantly. , 1998, European journal of biochemistry.

[24]  S. Lippard,et al.  Crystal Structure of the Anticancer Drug Cisplatin Bound to Duplex DNA , 1996 .

[25]  R. Halaban,et al.  UV-induced ubiquitination of RNA polymerase II: a novel modification deficient in Cockayne syndrome cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[26]  S. Lippard,et al.  Repair of cisplatin--DNA adducts by the mammalian excision nuclease. , 1996, Biochemistry.

[27]  S. Lippard,et al.  HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[28]  R H Sarma,et al.  Structural Biology: The State of the Art. , 1994, Journal of biomolecular structure & dynamics.

[29]  T. Cornelison,et al.  Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3. , 1993, Carcinogenesis.

[30]  S. Howell,et al.  Cellular accumulation of the anticancer agent cisplatin: a review. , 1993, British Journal of Cancer.

[31]  K. Comess,et al.  Replication inhibition and translesion synthesis on templates containing site-specifically placed cis-diamminedichloroplatinum(II) DNA adducts. , 1992, Biochemistry.

[32]  S. Lippard,et al.  Unwinding of supercoiled DNA by platinum-ethidium and related complexes , 1992 .

[33]  M. Caruthers Chemical Synthesis of DNA and DNA Analogues , 1992 .

[34]  M. Caruthers,et al.  Chemical synthesis of DNA and DNA analogs , 1991 .

[35]  W. Sundquist,et al.  Mechanistic studies of a novel class of trisubstituted platinum(II) antitumor agents. , 1991, Cancer research.

[36]  D A Scudiero,et al.  Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. , 1988, Cancer research.

[37]  F. Friedlos,et al.  Inherent sensitivity of cultured human embryonal carcinoma cells to adducts of cis-diamminedichloroplatinum(II) on DNA. , 1987, Cancer research.

[38]  A. V. van Oosterom,et al.  cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II). , 1987, Cancer research.

[39]  J. Barton,et al.  Binding of cis- and trans-dichlorodiammineplatinum(II) to DNA: evidence for unwinding and shortening of the double helix. , 1979, Science.

[40]  A. Sancar,et al.  Purification and characterization of Escherichia coli and human nucleotide excision repair enzyme systems. , 2006, Methods in enzymology.

[41]  S. Howell,et al.  Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. , 2005, Critical reviews in oncology/hematology.

[42]  N. Farrell Polynuclear platinum drugs. , 2004, Metal ions in biological systems.

[43]  E. Raymond,et al.  Cellular and molecular pharmacology of oxaliplatin. , 2002, Molecular cancer therapeutics.

[44]  L S Hollis,et al.  Chemical and biological properties of a new series of cis-diammineplatinum(II) antitumor agents containing three nitrogen donors: cis-[Pt(NH3)2(N-donor)Cl]+. , 1989, Journal of medicinal chemistry.

[45]  R. Baan,et al.  Immunochemical quantitation of adducts induced in DNA by cis-diamminedichloroplatinum (II) and analysis of adduct-related DNA-unwinding. , 1985, Chemico-Biological Interactions.